Study Evaluating Efficacy, Safety, and Tolerability of BI 1291583 qd
Status: Ongoing
Details
1397-0012 – A randomized, double-blind, placebo-controlled, parallel-group, dose-finding study evaluating efficacy, safety, and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis
Sponsor: BI
NCT05238675
